Dr. Reddy's Laboratories Ltd. - Research Center
500124 DRREDDY Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Dec' 22 | Sep' 22 | Jun' 22 | Mar' 22 | Dec' 21 | |
|---|---|---|---|---|---|
| Sales | 3,897.60 | 4,880.30 | 3,630.60 | 3,668.70 | 3,479.60 |
| Operating profit | 675.10 | 1,802.80 | 579.50 | 669.90 | 614.00 |
| Interest | 2.80 | 1.70 | 9.80 | 12.70 | 7.70 |
| Gross profit | 723.70 | 1,919.10 | 973.10 | 771.90 | 669.30 |
| EPS (Rs) | 19.48 | 67.09 | 30.02 | 25.22 | 20.50 |
Quarterly
results in details
| Dec' 22 | Sep' 22 | Jun' 22 | Mar' 22 | Dec' 21 | |
|---|---|---|---|---|---|
| Other income | 51.40 | 118.00 | 403.40 | 114.70 | 63.00 |
| Stock adjustment | -128.10 | 133.60 | 17.20 | -55.70 | -56.60 |
| Raw material | 865.90 | 636.70 | 804.70 | 1,014.90 | 507.80 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 708.40 | 710.10 | 649.00 | 608.90 | 604.00 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | 1,096.60 | 1,085.50 | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,776.30 | 1,597.10 | 483.60 | 335.40 | 1,810.40 |
| Provisions made | - | - | - | 9.80 | - |
| Depreciation | 238.80 | 226.20 | 221.50 | 205.20 | 205.40 |
| Taxation | 160.30 | 576.60 | 252.10 | 147.00 | 122.80 |
| Net profit / loss | 324.60 | 1,116.30 | 499.50 | 419.70 | 341.10 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 83.30 | 83.20 | 83.20 | 83.20 | 83.20 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 17.32 | 36.94 | 15.96 | 18.26 | 17.65 |
| GPM (%) | 18.33 | 38.40 | 24.12 | 20.40 | 18.89 |
| NPM (%) | 8.22 | 22.33 | 12.38 | 11.09 | 9.63 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis